Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupIndolent LymphomasDiseaseNHL, T-Cell Type, AngioimmunoblasticSubgroupICD10C86.5MeSHImmunoblastic LymphadenopathySequenceChemotherapyChemo-substanceCiclosporin AChemo-substanceCiclosporin AChemo-substanceCiclosporin AChemo-substanceCiclosporin ANo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentiondisease controlRisks only studiesPublicationAuthorAdvani RDiseaseAngioimmunoblastisches T-Zell-LymphomOriginStanford University Medical Center, Stanford, USAProtocols in Revision 1 protocol foundProtocols under revision.Ciclosporin 3, T-cell Lymphoma (PID2872 V1.0)
